PDCD1 and glioblastoma: These studies included a clinical trial assessing neoadjuvant anti-PD−1 immunotherapy with pembrolizumab (n = 35) [26] and a retrospective series of 66 adult GBM patients treated with PD−1 inhibitors (pembrolizumab or nivolumab) upon recurrence [25].